Role of Plasmapheresis Performed in Hemodialysis Units for the Treatment of Anti-Neutrophilic Cytoplasmic Antibody-Associated Systemic Vasculitides

Therapeutic Apheresis and Dialysis

Volumn 15, Issue 5, 2011, Pages 493-498

  Aydin, Zeki ^a   Gursu, Meltem ^a   Karadag, Serhat ^a   Uzun, Sami ^a   Tatli, Emel ^a   Sumnu, Abdullah ^a   Ozturk, Savas ^a   Kazancioglu, Rumeyza ^a  

^a HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Anti neutrophilic cytoplasmic antibody; Microscopic polyangiitis; Vasculitis; Wegener's granulomatosis

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; UREA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLOMERULONEPHRITIS; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LUNG HEMORRHAGE; MAINTENANCE THERAPY; MALE; MICROSCOPIC POLYANGIITIS; MORTALITY; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SYSTEMIC VASCULITIS; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; MICROSCOPIC POLYANGIITIS; MIDDLE AGED; PLASMAPHERESIS; PULSE THERAPY, DRUG; REMISSION INDUCTION; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS; YOUNG ADULT;

EID: 80955179973     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2011.00960.x     Document Type: Article

References (14)

1. Hoffman GS, Kerr GS, Leavitt RY etal. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
2. Savage CO, Winearls CG, Evans DJ, Rees AJ, Lockwood CM. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985;56:467-83.
3. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004;117:39.
4. Jayne DR, Gaskin G, Rasmussen N etal. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180.
5. Gallagher H, Kwan JT, Jayne DR. Pulmonary renal syndrome: a 4-year, single-center experience. Am J Kidney Dis 2002;39:42.
6. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003;42:1149-53.
7. Kaplan AA. Apheresis for renal disease. Ther Apher 2001;5:134-41.
8. Luqmani RA, Bacon PA, Moots RJ etal. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8.
9. Merkel PA, Seo P, Aries P etal. Vasculitis Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. Clinical Research Consortium, OMERACT 7 Special Interest Group. J Rheumatol 2005;32:2488-95.
10. Suppiah R, Mukhtyar C, Flossmann O etal. A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology 2011;50:899-905.
11. Cole E, Cattran D, Magil A etal. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis 1992;20:261-9.
12. Zäuner I, Bach D, Braun N etal. Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis 2002;39:28-35.
13. Gaskin G, Pusey CD. Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Ther Apher 2001;5:176-81.
14. Yamagata K, Hirayama K, Mase K etal. Apheresis for MPO-ANCA-associated RPGN-indications and efficacy: lessons learned from Japan nationwide survey of RPGN. J Clin Apher 2005;20:244-51.